{"protocolSection": {"identificationModule": {"nctId": "NCT05139615", "orgStudyIdInfo": {"id": "APD418-201"}, "secondaryIdInfos": [{"id": "C5061001", "type": "OTHER", "domain": "Alias Study Number"}, {"id": "2020-006131-10", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Pfizer", "class": "INDUSTRY"}, "briefTitle": "A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction", "officialTitle": "A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of APD418 in Subjects With Heart Failure With Reduced Ejection Fraction"}, "statusModule": {"statusVerifiedDate": "2023-11", "overallStatus": "TERMINATED", "whyStopped": "Business decision", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2021-12-28", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-09-19", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-09-19", "type": "ACTUAL"}, "studyFirstSubmitDate": "2021-11-18", "studyFirstSubmitQcDate": "2021-11-18", "studyFirstPostDateStruct": {"date": "2021-12-01", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-09-18", "resultsFirstSubmitQcDate": "2023-11-06", "resultsFirstPostDateStruct": {"date": "2023-11-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-11-06", "lastUpdatePostDateStruct": {"date": "2023-11-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Pfizer", "class": "INDUSTRY"}, "collaborators": [{"name": "Arena is a wholly owned subsidiary of Pfizer", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the safety, pharmacokinetics, and effect on cardiac function of intravenous APD418 in adult participants with heart failure with reduced ejection fraction (HFrEF).", "detailedDescription": "This study has an adaptive design, in which dose escalation in Part A will inform dose expansion in Part B. Part A is a single-ascending dose, placebo-controlled study planned to consist of 5 cohorts evaluating 5 doses of APD418. Part B is a parallel-treatment group study planned to evaluate 2 doses of APD418 and placebo. Participants in Part A cannot participate in Part B."}, "conditionsModule": {"conditions": ["Acute Heart Failure With Reduced Ejection Fraction"], "keywords": ["Heart failure with reduced ejection fraction", "HFrEF", "APD418", "Acute Heart Failure (AHF)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 22, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "APD418 (Part A: Dose Cohort 1-5)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: APD418"]}, {"label": "APD418 (Part B: Dose Group 1 and 2)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: APD418"]}, {"label": "Placebo (Part A: Cohort 1-5 and Part B)", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "APD418", "description": "Participants will receive a single dose of APD418 as an intravenous (IV) infusion.", "armGroupLabels": ["APD418 (Part A: Dose Cohort 1-5)"]}, {"type": "DRUG", "name": "APD418", "description": "Participants will receive a single dose of APD418 as an IV infusion.", "armGroupLabels": ["APD418 (Part B: Dose Group 1 and 2)"]}, {"type": "DRUG", "name": "Placebo", "description": "Participants will receive a single dose of APD418 matching placebo as an IV infusion.", "armGroupLabels": ["Placebo (Part A: Cohort 1-5 and Part B)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Part A: Change in Cardiac Index (CI) Measured by Right Heart Catheterization (RHC) From Baseline to End of Intravenous (IV) Infusion at 6 Hours", "description": "Cardiac index (CI) is a hemodynamic parameter that relates the cardiac output (CO) from left ventricle in one minute to body surface area (BSA), thus relating heart performance to the body size of the participant. It was measured by RHC.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)"}], "secondaryOutcomes": [{"measure": "Part A: Change in Stroke Volume (SV), Left Ventricular End-Systolic Volume (LVESV) and Left Ventricular End-Diastolic Volume (LVEDV) Measured by Echocardiogram (ECHO) From Baseline to End of IV Infusion at 6 Hours", "description": "SV is the volume of blood pumped from the left ventricle per beat. LVESV is the volume of blood in the left ventricle at the end of contraction and at diastole. LVEDV is the amount of blood in the heart's left ventricle just before the heart contracts. All these parameters were measured by ECHO.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)"}, {"measure": "Part A: Change in Stroke Volume Index (SVI) Measured by ECHO From Baseline to End of IV Infusion at 6 Hours", "description": "SVI was calculated as stroke volume divided by BSA. This was measured by ECHO.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)"}, {"measure": "Part A: Change in Left Ventricular Ejection Fraction (LVEF) Measured by ECHO From Baseline to End of IV Infusion at 6 Hours", "description": "LVEF is the central measure of left ventricular systolic function. LVEF is the fraction of chamber volume ejected in systole (stroke volume) in relation to the volume of the blood in the ventricle at the end of diastole (end-diastolic volume). This was measured by ECHO.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)"}, {"measure": "Part A: Change in Fractional Shortening (FS) Measured by ECHO From Baseline to End of IV Infusion at 6 Hours", "description": "FS was calculated by measuring the percentage reduction in left ventricular diameter during systole. This was measured by ECHO.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)"}, {"measure": "Part A: Change in Left Ventricular End-Systolic and Left Ventricular End-Diastolic Diameter Measured by ECHO From Baseline to End of IV Infusion at 6 Hours", "description": "Left ventricular end-systolic diameter and left ventricular end-diastolic diameter were measured using ECHO.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)"}, {"measure": "Part A: Change in Left Ventricular Global Longitudinal Strain (LVGLS) and Left Ventricular Global Circumferential Strain (LVGCS) Measured by ECHO From Baseline to End of IV Infusion at 6 Hours", "description": "Left ventricular global strain is the average strain of the cardiac chamber wall, where LVGLS presents longitudinal shortening as a percentage (change in length as a proportion to baseline length). LVGCS measures the chamber deformation along the circumference of the cardiac wall in a tangential xy-direction and similarly presents the circumferential shortening as a percentage. Both the parameters were measured by ECHO.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)"}, {"measure": "Part A: Change in CI Measured by RHC at 0.5, 1, 2, 3, 4 and 5 Hours During 6 Hour IV Infusion", "description": "CI is a hemodynamic parameter that relates the CO from left ventricle in one minute to BSA, thus relating heart performance to the body size of the participant. It was measured by RHC.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4 and 5 hours of IV infusion"}, {"measure": "Part A: Change in Cardiac Output (CO) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "Change in CO measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6-hour IV infusion was reported in this outcome measure.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion"}, {"measure": "Part A: Change in Pulmonary Capillary Wedge Pressure (PCWP), Right Atrial Pressure (RAP), Systolic Pulmonary Arterial Pressure/Diastolic Pulmonary Arterial Pressure (PAS/PAD) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "PCWP estimated the left atrial pressure and was the pressure measured by wedging a pulmonary artery catheter with an inflated balloon into a small pulmonary arterial branch. PCWP was assessed by 2 successive measurements at least 10 minutes apart. RAP is the blood pressure in the right atrium of the heart. Change in PCWP, RAP, PAS/PAD at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6-hour IV infusion was reported in this outcome measure. All the parameters were measured by RHC.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion"}, {"measure": "Part A: Change in Pulmonary Artery Pulsatility Index (PAPi) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "PAPi is a hemodynamic parameter that is derived from right atrial and pulmonary artery pulse pressures. PAPi = (PAS - PAD)/right atrial pressure. Change in PAPi measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6-hour IV infusion was reported in this outcome measure.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion"}, {"measure": "Part A: Change in Systemic Vascular Resistance Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "Systemic vascular resistance (SVR) is the amount of force exerted on circulating blood by the vasculature of the body. SVR was calculated as 80\\*(mean arterial pressure - mean venous pressure) divided by cardiac output. Change in SVR measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6-hour IV infusion was reported in this outcome measure.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion"}, {"measure": "Part A: Change in Systemic Vascular Resistance Index (SVRI) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "SVRI was calculated by dividing the difference between mean arterial pressure and central venous pressure by cardiac index and multiplying by 80. Change in SVRI measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6 hour IV infusion was reported in this outcome measure.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion"}, {"measure": "Part A: Change in Pulmonary Vascular Resistance (PVR) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "PVR is the resistance against blood flow from the pulmonary artery to the left atrium. Change in PVR measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6 hour IV infusion was reported in this outcome measure.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion"}, {"measure": "Part A: Change in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "SBP, DBP and MAP were measured in a supine or seated position after participant had at least 5 minutes of rest. MAP is the average pressure of the blood circulating through a participant's arteries during the cardiac cycle. MAP was derived by using the following formula: DBP + 1/3(SBP-DBP).", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion"}, {"measure": "Part A: Change in Heart Rate at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "Heart rate was measured in a supine or seated position after participant had at least 5 minutes of rest.", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion"}, {"measure": "Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)", "description": "An AE was any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. TEAEs were defined as those AEs with onset after start date/timepoint of study drug administration.", "timeFrame": "From start of study treatment on Day 1 up to Day 9"}, {"measure": "Part A: Area Under the Plasma Concentration Time Curve From Time Zero to 6 Hours (AUC[0-6]) of APD418", "description": "AUC \\[0-6\\] was reported in this outcome measure.", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6 hours post infusion start"}, {"measure": "Part A: Area Under the Plasma Concentration Time Curve From Time Zero to Last Quantifiable Plasma Concentration (AUCLast) of APD418", "description": "AUClast was reported in this outcome measure.", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start"}, {"measure": "Part A: Area Under the Plasma Concentration Time Curve From Time Zero up to Infinity (AUC[0-Infinity]) of APD418", "description": "AUC \\[0-infinity\\] was reported in this outcome measure.", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start"}, {"measure": "Part A: Maximum Observed Plasma Concentration (Cmax) of APD418", "description": "Cmax of APD418 was reported in this outcome measure.", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start"}, {"measure": "Part A: Terminal Elimination Half-Life (t1/2) for APD418", "description": "Terminal t1/2 of APD418 was reported in this outcome measure.", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start"}, {"measure": "Part A: Distributional Half-Life (t1/2a) for APD418", "description": "Distributional t1/2 of APD418 was reported in this outcome measure.", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start"}, {"measure": "Part A: Time to Maximum Observed Plasma Concentration (Tmax) for APD418", "description": "Tmax of APD418 was reported in this outcome measure.", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start"}, {"measure": "Part A: Total Clearance (CL) for APD418", "description": "IV CL of APD418 was reported in this outcome measure.", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start"}, {"measure": "Part A: Total Volume of Distribution Based on the Terminal Phase (Vdz) for APD418", "description": "Vdz of APD418 was reported in this outcome measure.", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start"}, {"measure": "Part A: Volume of Distribution at Steady State (Vdss) for APD418", "description": "Vdss of APD418 was reported in this outcome measure.", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start"}, {"measure": "Part A: Mean Residence Time From Time Zero to Time of Last Quantifiable Plasma Concentration (MRTlast) for APD418", "description": "MRTlast of APD418 was reported in this outcome measure.", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start"}, {"measure": "Part A: Average Plasma Concentration During Dosing Interval (Cave) for ADP418", "description": "Average plasma concentration calculated over the 6-hour infusion time was reported in this outcome measure.", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6 hours post infusion start"}, {"measure": "Part A: Renal Clearance (CLr) for ADP418", "description": "CLr for APD418 was reported in this outcome measure.", "timeFrame": "Pre-dose (0) to 24 hours post infusion start, collected over 0 to 6 hour, 6 to 10 hour and 10 to 24-hour intervals"}], "otherOutcomes": [{"measure": "Part A: Amount of Unchanged Drug Excreted in Urine During Each Collection Interval From t1 to t2 (Aet1-t2)", "description": "Amount of unchanged drug excreted in urine during each collection interval from t1 to t2 was reported in this outcome measure.", "timeFrame": "Anytime between 0 to 6 hours, 6 to 10 hours and 10 to 24 hours post infusion start"}, {"measure": "Part A: Total Amount of Unchanged Drug Excreted in Urine Over the Collection Period (Amount Excreted [Ae])", "description": "Total amount of unchanged drug excreted in urine over the collection period was reported in this outcome measure.", "timeFrame": "Pre-dose (0) to 24 hours post infusion start, collected over 0 to 6 hour, 6 to 10 hour and 10 to 24-hour intervals"}, {"measure": "Part A: Fraction of Drug Excreted Unchanged (Fe) in Urine", "description": "Fraction of drug excreted in urine was reported in this outcome measure. Data is presented in terms of percentages.", "timeFrame": "Pre-dose (0) to 24 hours post infusion start, collected over 0 to 6 hour, 6 to 10 hour and 10 to 24-hour intervals"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Advanced chronic Heart Failure with Reduced Ejection Fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) less than or equal to (\u2264) 35% at Screening, including documented history of HFrEF (LVEF \u2264 35%) for at least 4 months prior to Screening\n* New York Heart Association Class II-IV\n* Cardiac index \u2264 2.5 liters per minute per square meter (L/min/m\\^2) and pulmonary capillary wedge pressure \u2265 15 millimeters of mercury (mm Hg) at Day 1\n* Body mass index 18.0 to 37.0 kilograms per square meter (kg/m\\^2), inclusive, and body weight \\< 150 kg at Screening and Day 1\n\nExclusion Criteria:\n\n* Hemodynamically unstable at Day 1 or in the opinion of the Investigator likely to progress to becoming hemodynamically unstable during the course of the study\n* Treated with carvedilol or at a dose higher than a total of 25 milligrams per day any time within 72 hours of Day 1 through the end of the in-clinic observation Post-dose Period.\n* Receiving any mechanical (respiratory or circulatory) or renal support therapy at Screening or Day 1\n* Systolic Blood Pressure \u2264 90 millimeter of mercury (mm Hg) or \u2265 160 mm Hg, or Heart Rate \\< 50 beats per minute (bpm) or \\> 110 bpm, at Screening or Day 1\n* Recently treated with inotropic, intravenous (IV) vasoactive or IV diuretic therapy, or expected to require such therapy with these drugs any time from Day 1 through the end of study conduct.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "85 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pfizer CT.gov Call Center", "affiliation": "Pfizer", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "James A. Haley Veterans' Hospital", "city": "Tampa", "state": "Florida", "zip": "33612", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "UnityPoint Health - Methodist Hospital", "city": "Peoria", "state": "Illinois", "zip": "61606", "country": "United States", "geoPoint": {"lat": 40.69365, "lon": -89.58899}}, {"facility": "UTHealth", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Health Science Center Utah", "city": "Salt Lake City", "state": "Utah", "zip": "84132", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "University of Wisconsin", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Immanuel Hospital Bernau Brandenburg Heart Center", "city": "Bernau bei Berlin", "state": "Brandenburg", "zip": "16321", "country": "Germany", "geoPoint": {"lat": 52.67982, "lon": 13.58708}}, {"facility": "Kerckhoff-Klinik Forschungsgesellschaft GmbH", "city": "Bad Nauheim", "zip": "61231", "country": "Germany", "geoPoint": {"lat": 50.36463, "lon": 8.73859}}, {"facility": "Universitatsmedizin Greifwald", "city": "Greifswald", "zip": "17475", "country": "Germany", "geoPoint": {"lat": 54.09311, "lon": 13.38786}}, {"facility": "Konstantinopouleio General Hospital of Nea Ionia - Patision ''Agia Olga''", "city": "Nea Ionia", "state": "Athens", "zip": "14233", "country": "Greece", "geoPoint": {"lat": 38.0357, "lon": 23.75733}}, {"facility": "Interbalkan European Medical Center", "city": "Pylaia", "state": "Thessaloniki", "zip": "55535", "country": "Greece", "geoPoint": {"lat": 40.59918, "lon": 22.98613}}, {"facility": "General University Hospital of Larissa", "city": "Larissa", "zip": "41110", "country": "Greece", "geoPoint": {"lat": 39.63689, "lon": 22.41761}}, {"facility": "American Heart of Poland S.A.", "city": "Gniezno", "zip": "62-200", "country": "Poland", "geoPoint": {"lat": 52.53481, "lon": 17.58259}}, {"facility": "Krakowski Szpital Specjalistyczny im. Jana Pawla II", "city": "Krakow", "zip": "31-202", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Uniwersytecki Szpital Kliniczny im Jana Mikulicza-Radeckiego", "city": "Wroclaw", "zip": "50-556", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Clinical Hospital Centre Zemun", "city": "Belgrade", "zip": "11 070", "country": "Serbia", "geoPoint": {"lat": 44.80401, "lon": 20.46513}}, {"facility": "University Clinical Centre of Serbia", "city": "Belgrade", "zip": "11000", "country": "Serbia", "geoPoint": {"lat": 44.80401, "lon": 20.46513}}, {"facility": "Institute for Cardiovascular Diseases Dedinje", "city": "Belgrade", "zip": "11040", "country": "Serbia", "geoPoint": {"lat": 44.80401, "lon": 20.46513}}, {"facility": "Clinical Hospital Center Bezanijska Kosa", "city": "Belgrade", "zip": "11080", "country": "Serbia", "geoPoint": {"lat": 44.80401, "lon": 20.46513}}, {"facility": "Clinical Center of Kragujevac", "city": "Kragujevac", "zip": "34000", "country": "Serbia", "geoPoint": {"lat": 44.01667, "lon": 20.91667}}, {"facility": "Institute for Cardiovascular Diseases of Vojvodina", "city": "Sremska Kamenica", "zip": "21204", "country": "Serbia", "geoPoint": {"lat": 45.22158, "lon": 19.84367}}, {"facility": "Healthcare Center Uzice", "city": "U\u017eice", "zip": "31000", "country": "Serbia", "geoPoint": {"lat": 43.85861, "lon": 19.84878}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "To obtain contact information for a study center near you, click here.", "url": "https://pmiform.com/clinical-trial-info-request?StudyID=APD418-201"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.", "url": "https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study was planned to be conducted in two parts (Part A and B); however, study was terminated during Part A due to a business decision by Sponsor and Part B was not initiated and no participants were enrolled in Part B.", "groups": [{"id": "FG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "FG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "FG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "FG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "11"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "11"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment.", "groups": [{"id": "BG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "BG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "BG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "BG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "22"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "13"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "17"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "22"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "22"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Part A: Change in Cardiac Index (CI) Measured by Right Heart Catheterization (RHC) From Baseline to End of Intravenous (IV) Infusion at 6 Hours", "description": "Cardiac index (CI) is a hemodynamic parameter that relates the cardiac output (CO) from left ventricle in one minute to body surface area (BSA), thus relating heart performance to the body size of the participant. It was measured by RHC.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter per minute per meter square", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.33", "spread": "0.660"}, {"groupId": "OG001", "value": "0.10", "spread": "0.100"}, {"groupId": "OG002", "value": "0.25", "spread": "0.372"}, {"groupId": "OG003", "value": "0.10", "spread": "0.245"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Stroke Volume (SV), Left Ventricular End-Systolic Volume (LVESV) and Left Ventricular End-Diastolic Volume (LVEDV) Measured by Echocardiogram (ECHO) From Baseline to End of IV Infusion at 6 Hours", "description": "SV is the volume of blood pumped from the left ventricle per beat. LVESV is the volume of blood in the left ventricle at the end of contraction and at diastole. LVEDV is the amount of blood in the heart's left ventricle just before the heart contracts. All these parameters were measured by ECHO.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment. Here, 'Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Milliliter", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "Stroke Volume", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.13", "spread": "10.623"}, {"groupId": "OG001", "value": "-0.80", "spread": "NA", "comment": "Standard Deviation could not be calculated as a single participant was analyzed."}, {"groupId": "OG002", "value": "5.94", "spread": "10.183"}, {"groupId": "OG003", "value": "-3.15", "spread": "7.152"}]}]}, {"title": "LVESV", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.05", "spread": "22.837"}, {"groupId": "OG001", "value": "4.10", "spread": "NA", "comment": "Standard Deviation could not be calculated as a single participant was analyzed."}, {"groupId": "OG002", "value": "8.28", "spread": "25.689"}, {"groupId": "OG003", "value": "8.92", "spread": "29.804"}]}]}, {"title": "LVEDV", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.92", "spread": "15.531"}, {"groupId": "OG001", "value": "3.30", "spread": "NA", "comment": "Standard Deviation could not be calculated as a single participant was analyzed."}, {"groupId": "OG002", "value": "14.20", "spread": "31.021"}, {"groupId": "OG003", "value": "7.30", "spread": "38.006"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Stroke Volume Index (SVI) Measured by ECHO From Baseline to End of IV Infusion at 6 Hours", "description": "SVI was calculated as stroke volume divided by BSA. This was measured by ECHO.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment. Here, 'Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Milliliter per meter square", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.50", "spread": "5.518"}, {"groupId": "OG001", "value": "-0.30", "spread": "NA", "comment": "Standard Deviation could not be calculated as a single participant was analyzed."}, {"groupId": "OG002", "value": "2.62", "spread": "4.615"}, {"groupId": "OG003", "value": "-2.00", "spread": "4.492"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Left Ventricular Ejection Fraction (LVEF) Measured by ECHO From Baseline to End of IV Infusion at 6 Hours", "description": "LVEF is the central measure of left ventricular systolic function. LVEF is the fraction of chamber volume ejected in systole (stroke volume) in relation to the volume of the blood in the ventricle at the end of diastole (end-diastolic volume). This was measured by ECHO.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of end diastolic volume", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.90", "spread": "6.009"}, {"groupId": "OG001", "value": "0.47", "spread": "1.457"}, {"groupId": "OG002", "value": "1.14", "spread": "3.204"}, {"groupId": "OG003", "value": "-1.68", "spread": "0.900"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Fractional Shortening (FS) Measured by ECHO From Baseline to End of IV Infusion at 6 Hours", "description": "FS was calculated by measuring the percentage reduction in left ventricular diameter during systole. This was measured by ECHO.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.60", "spread": "7.791"}, {"groupId": "OG001", "value": "0.47", "spread": "5.710"}, {"groupId": "OG002", "value": "-1.55", "spread": "1.924"}, {"groupId": "OG003", "value": "-4.50", "spread": "7.444"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Left Ventricular End-Systolic and Left Ventricular End-Diastolic Diameter Measured by ECHO From Baseline to End of IV Infusion at 6 Hours", "description": "Left ventricular end-systolic diameter and left ventricular end-diastolic diameter were measured using ECHO.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Centimeter (cm)", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "Left ventricular end-systolic diameter", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "spread": "0.361"}, {"groupId": "OG001", "value": "-0.04", "spread": "0.384"}, {"groupId": "OG002", "value": "0.22", "spread": "0.321"}, {"groupId": "OG003", "value": "0.35", "spread": "0.544"}]}]}, {"title": "Left ventricular end-diastolic diameter", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.04", "spread": "0.087"}, {"groupId": "OG001", "value": "-0.02", "spread": "0.098"}, {"groupId": "OG002", "value": "0.15", "spread": "0.363"}, {"groupId": "OG003", "value": "0.16", "spread": "0.243"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Left Ventricular Global Longitudinal Strain (LVGLS) and Left Ventricular Global Circumferential Strain (LVGCS) Measured by ECHO From Baseline to End of IV Infusion at 6 Hours", "description": "Left ventricular global strain is the average strain of the cardiac chamber wall, where LVGLS presents longitudinal shortening as a percentage (change in length as a proportion to baseline length). LVGCS measures the chamber deformation along the circumference of the cardiac wall in a tangential xy-direction and similarly presents the circumferential shortening as a percentage. Both the parameters were measured by ECHO.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment. Here, 'Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable for the specified rows.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration) up to 6 Hours (end of IV infusion)", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "LVGLS", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.30", "spread": "NA", "comment": "Standard Deviation could not be calculated as a single participant was analyzed."}, {"groupId": "OG001", "value": "-1.10", "spread": "NA", "comment": "Standard Deviation could not be calculated as a single participant was analyzed."}, {"groupId": "OG002", "value": "1.10", "spread": "1.337"}, {"groupId": "OG003", "value": "-1.29", "spread": "0.987"}]}]}, {"title": "LVGCS", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "2"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.70", "spread": "NA", "comment": "Standard Deviation could not be calculated as a single participant was analyzed."}, {"groupId": "OG002", "value": "0.05", "spread": "2.105"}, {"groupId": "OG003", "value": "0.00", "spread": "3.111"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in CI Measured by RHC at 0.5, 1, 2, 3, 4 and 5 Hours During 6 Hour IV Infusion", "description": "CI is a hemodynamic parameter that relates the CO from left ventricle in one minute to BSA, thus relating heart performance to the body size of the participant. It was measured by RHC.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter per minute per meter square", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4 and 5 hours of IV infusion", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "0.5 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "0.252"}, {"groupId": "OG001", "value": "0.27", "spread": "0.379"}, {"groupId": "OG002", "value": "0.10", "spread": "0.167"}, {"groupId": "OG003", "value": "-0.10", "spread": "0.183"}]}]}, {"title": "1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.35", "spread": "0.252"}, {"groupId": "OG001", "value": "0.27", "spread": "0.379"}, {"groupId": "OG002", "value": "0.06", "spread": "0.112"}, {"groupId": "OG003", "value": "0.05", "spread": "0.208"}]}]}, {"title": "2 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.45", "spread": "0.370"}, {"groupId": "OG001", "value": "0.13", "spread": "0.058"}, {"groupId": "OG002", "value": "0.11", "spread": "0.104"}, {"groupId": "OG003", "value": "-0.08", "spread": "0.126"}]}]}, {"title": "3 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "spread": "0.427"}, {"groupId": "OG001", "value": "0.20", "spread": "0.265"}, {"groupId": "OG002", "value": "0.20", "spread": "0.279"}, {"groupId": "OG003", "value": "0.15", "spread": "0.129"}]}]}, {"title": "4 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.25", "spread": "0.100"}, {"groupId": "OG001", "value": "0.10", "spread": "0.100"}, {"groupId": "OG002", "value": "0.09", "spread": "0.221"}, {"groupId": "OG003", "value": "0.10", "spread": "0.346"}]}]}, {"title": "5 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.23", "spread": "0.457"}, {"groupId": "OG001", "value": "0.17", "spread": "0.153"}, {"groupId": "OG002", "value": "0.11", "spread": "0.274"}, {"groupId": "OG003", "value": "0.08", "spread": "0.096"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Cardiac Output (CO) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "Change in CO measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6-hour IV infusion was reported in this outcome measure.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter per minute", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "0.5 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.15", "spread": "0.420"}, {"groupId": "OG001", "value": "0.63", "spread": "0.777"}, {"groupId": "OG002", "value": "0.20", "spread": "0.329"}, {"groupId": "OG003", "value": "-0.15", "spread": "0.300"}]}]}, {"title": "1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "spread": "0.457"}, {"groupId": "OG001", "value": "0.67", "spread": "0.907"}, {"groupId": "OG002", "value": "0.15", "spread": "0.230"}, {"groupId": "OG003", "value": "0.13", "spread": "0.340"}]}]}, {"title": "2 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.90", "spread": "0.876"}, {"groupId": "OG001", "value": "0.43", "spread": "0.231"}, {"groupId": "OG002", "value": "0.21", "spread": "0.212"}, {"groupId": "OG003", "value": "-0.08", "spread": "0.189"}]}]}, {"title": "3 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.28", "spread": "0.877"}, {"groupId": "OG001", "value": "0.47", "spread": "0.643"}, {"groupId": "OG002", "value": "0.41", "spread": "0.568"}, {"groupId": "OG003", "value": "0.33", "spread": "0.299"}]}]}, {"title": "4 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.43", "spread": "0.222"}, {"groupId": "OG001", "value": "0.27", "spread": "0.231"}, {"groupId": "OG002", "value": "0.18", "spread": "0.467"}, {"groupId": "OG003", "value": "0.20", "spread": "0.560"}]}]}, {"title": "5 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.43", "spread": "0.911"}, {"groupId": "OG001", "value": "0.43", "spread": "0.379"}, {"groupId": "OG002", "value": "0.25", "spread": "0.559"}, {"groupId": "OG003", "value": "0.15", "spread": "0.191"}]}]}, {"title": "6 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.75", "spread": "1.420"}, {"groupId": "OG001", "value": "0.30", "spread": "0.346"}, {"groupId": "OG002", "value": "0.53", "spread": "0.742"}, {"groupId": "OG003", "value": "0.23", "spread": "0.499"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Pulmonary Capillary Wedge Pressure (PCWP), Right Atrial Pressure (RAP), Systolic Pulmonary Arterial Pressure/Diastolic Pulmonary Arterial Pressure (PAS/PAD) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "PCWP estimated the left atrial pressure and was the pressure measured by wedging a pulmonary artery catheter with an inflated balloon into a small pulmonary arterial branch. PCWP was assessed by 2 successive measurements at least 10 minutes apart. RAP is the blood pressure in the right atrium of the heart. Change in PCWP, RAP, PAS/PAD at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6-hour IV infusion was reported in this outcome measure. All the parameters were measured by RHC.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment. All participants reported under 'Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row. Here, 'Number Analyzed' (n) signifies number of participants evaluable for specified timepoints.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Millimeters of mercury", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "PCWP: 0.5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.50", "spread": "2.887"}, {"groupId": "OG001", "value": "0.67", "spread": "3.055"}, {"groupId": "OG002", "value": "-0.78", "spread": "3.456"}, {"groupId": "OG003", "value": "-2.67", "spread": "4.726"}]}]}, {"title": "PCWP: 1 hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.25", "spread": "8.808"}, {"groupId": "OG001", "value": "-2.33", "spread": "4.041"}, {"groupId": "OG002", "value": "-2.00", "spread": "2.828"}, {"groupId": "OG003", "value": "-2.67", "spread": "8.145"}]}]}, {"title": "PCWP: 2 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.50", "spread": "5.000"}, {"groupId": "OG001", "value": "-3.33", "spread": "1.528"}, {"groupId": "OG002", "value": "1.56", "spread": "3.609"}, {"groupId": "OG003", "value": "-0.67", "spread": "7.506"}]}]}, {"title": "PCWP: 3 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.75", "spread": "3.594"}, {"groupId": "OG001", "value": "-0.33", "spread": "4.509"}, {"groupId": "OG002", "value": "-3.67", "spread": "3.464"}, {"groupId": "OG003", "value": "-3.67", "spread": "7.506"}]}]}, {"title": "PCWP: 4 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.75", "spread": "3.948"}, {"groupId": "OG001", "value": "-0.67", "spread": "5.033"}, {"groupId": "OG002", "value": "-2.90", "spread": "5.384"}, {"groupId": "OG003", "value": "-5.00", "spread": "9.165"}]}]}, {"title": "PCWP: 5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.50", "spread": "6.137"}, {"groupId": "OG001", "value": "-1.33", "spread": "6.110"}, {"groupId": "OG002", "value": "-1.56", "spread": "2.698"}, {"groupId": "OG003", "value": "-3.33", "spread": "9.018"}]}]}, {"title": "PCWP: 6 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.75", "spread": "7.411"}, {"groupId": "OG001", "value": "-1.67", "spread": "5.686"}, {"groupId": "OG002", "value": "-1.25", "spread": "2.315"}, {"groupId": "OG003", "value": "-1.67", "spread": "9.504"}]}]}, {"title": "RAP: 0.5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.50", "spread": "1.291"}, {"groupId": "OG001", "value": "0.00", "spread": "1.732"}, {"groupId": "OG002", "value": "1.40", "spread": "3.836"}, {"groupId": "OG003", "value": "-1.33", "spread": "2.517"}]}]}, {"title": "RAP: 1 hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.50", "spread": "3.317"}, {"groupId": "OG001", "value": "0.33", "spread": "2.309"}, {"groupId": "OG002", "value": "0.00", "spread": "2.867"}, {"groupId": "OG003", "value": "3.33", "spread": "6.658"}]}]}, {"title": "RAP: 2 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "spread": "0.816"}, {"groupId": "OG001", "value": "-1.00", "spread": "1.000"}, {"groupId": "OG002", "value": "1.00", "spread": "4.397"}, {"groupId": "OG003", "value": "2.67", "spread": "7.234"}]}]}, {"title": "RAP: 3 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.25", "spread": "1.258"}, {"groupId": "OG001", "value": "0.33", "spread": "2.517"}, {"groupId": "OG002", "value": "0.40", "spread": "2.366"}, {"groupId": "OG003", "value": "3.33", "spread": "8.505"}]}]}, {"title": "RAP: 4 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.75", "spread": "4.500"}, {"groupId": "OG001", "value": "-0.67", "spread": "1.155"}, {"groupId": "OG002", "value": "-0.20", "spread": "4.315"}, {"groupId": "OG003", "value": "4.00", "spread": "6.083"}]}]}, {"title": "RAP: 5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.50", "spread": "3.416"}, {"groupId": "OG001", "value": "-2.67", "spread": "1.155"}, {"groupId": "OG002", "value": "0.50", "spread": "4.301"}, {"groupId": "OG003", "value": "1.67", "spread": "8.327"}]}]}, {"title": "RAP: 6 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.67", "spread": "4.041"}, {"groupId": "OG001", "value": "-1.67", "spread": "1.528"}, {"groupId": "OG002", "value": "-0.50", "spread": "5.233"}, {"groupId": "OG003", "value": "4.00", "spread": "8.660"}]}]}, {"title": "PAS: 0.5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.50", "spread": "5.196"}, {"groupId": "OG001", "value": "-1.00", "spread": "2.646"}, {"groupId": "OG002", "value": "0.20", "spread": "6.033"}, {"groupId": "OG003", "value": "-0.67", "spread": "6.110"}]}]}, {"title": "PAS: 1 hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.50", "spread": "9.147"}, {"groupId": "OG001", "value": "-0.67", "spread": "4.041"}, {"groupId": "OG002", "value": "-1.50", "spread": "4.859"}, {"groupId": "OG003", "value": "-0.67", "spread": "6.028"}]}]}, {"title": "PAS: 2 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.25", "spread": "4.717"}, {"groupId": "OG001", "value": "0.67", "spread": "0.577"}, {"groupId": "OG002", "value": "0.90", "spread": "6.740"}, {"groupId": "OG003", "value": "0.33", "spread": "4.933"}]}]}, {"title": "PAS: 3 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.25", "spread": "6.185"}, {"groupId": "OG001", "value": "1.67", "spread": "5.033"}, {"groupId": "OG002", "value": "-1.40", "spread": "9.383"}, {"groupId": "OG003", "value": "-3.33", "spread": "9.292"}]}]}, {"title": "PAS: 4 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.75", "spread": "13.525"}, {"groupId": "OG001", "value": "2.00", "spread": "4.359"}, {"groupId": "OG002", "value": "-1.70", "spread": "6.201"}, {"groupId": "OG003", "value": "-8.33", "spread": "15.631"}]}]}, {"title": "PAS: 5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.00", "spread": "11.195"}, {"groupId": "OG001", "value": "5.00", "spread": "1.000"}, {"groupId": "OG002", "value": "-1.30", "spread": "6.945"}, {"groupId": "OG003", "value": "-1.33", "spread": "6.658"}]}]}, {"title": "PAS: 6 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.25", "spread": "9.179"}, {"groupId": "OG001", "value": "2.67", "spread": "2.309"}, {"groupId": "OG002", "value": "-0.90", "spread": "8.569"}, {"groupId": "OG003", "value": "-4.33", "spread": "9.609"}]}]}, {"title": "PAD: 0.5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.25", "spread": "3.500"}, {"groupId": "OG001", "value": "0.00", "spread": "0.000"}, {"groupId": "OG002", "value": "-1.00", "spread": "2.789"}, {"groupId": "OG003", "value": "0.33", "spread": "4.509"}]}]}, {"title": "PAD: 1 hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.50", "spread": "2.646"}, {"groupId": "OG001", "value": "-1.33", "spread": "0.577"}, {"groupId": "OG002", "value": "-0.90", "spread": "3.872"}, {"groupId": "OG003", "value": "-1.67", "spread": "4.041"}]}]}, {"title": "PAD: 2 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.25", "spread": "2.217"}, {"groupId": "OG001", "value": "-0.67", "spread": "2.517"}, {"groupId": "OG002", "value": "-0.70", "spread": "3.860"}, {"groupId": "OG003", "value": "-1.00", "spread": "3.000"}]}]}, {"title": "PAD: 3 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.25", "spread": "4.193"}, {"groupId": "OG001", "value": "1.00", "spread": "2.646"}, {"groupId": "OG002", "value": "-3.60", "spread": "5.168"}, {"groupId": "OG003", "value": "0.00", "spread": "6.245"}]}]}, {"title": "PAD: 4 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.50", "spread": "8.888"}, {"groupId": "OG001", "value": "1.33", "spread": "1.155"}, {"groupId": "OG002", "value": "-2.40", "spread": "4.061"}, {"groupId": "OG003", "value": "-3.00", "spread": "7.937"}]}]}, {"title": "PAD: 5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.50", "spread": "4.041"}, {"groupId": "OG001", "value": "1.00", "spread": "2.646"}, {"groupId": "OG002", "value": "-2.40", "spread": "3.688"}, {"groupId": "OG003", "value": "1.33", "spread": "5.033"}]}]}, {"title": "PAD: 6 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.00", "spread": "5.831"}, {"groupId": "OG001", "value": "1.33", "spread": "3.215"}, {"groupId": "OG002", "value": "-1.80", "spread": "4.984"}, {"groupId": "OG003", "value": "0.67", "spread": "5.686"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Pulmonary Artery Pulsatility Index (PAPi) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "PAPi is a hemodynamic parameter that is derived from right atrial and pulmonary artery pulse pressures. PAPi = (PAS - PAD)/right atrial pressure. Change in PAPi measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6-hour IV infusion was reported in this outcome measure.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment. All participants reported under 'Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row. Here, 'Number Analyzed' (n) signifies number of participants evaluable for specified timepoints.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "PAPi: 0.5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.28", "spread": "0.411"}, {"groupId": "OG001", "value": "-0.17", "spread": "0.833"}, {"groupId": "OG002", "value": "-0.11", "spread": "0.713"}, {"groupId": "OG003", "value": "0.37", "spread": "1.343"}]}]}, {"title": "PAPi: 1 hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.08", "spread": "0.562"}, {"groupId": "OG001", "value": "0.17", "spread": "0.306"}, {"groupId": "OG002", "value": "-0.21", "spread": "0.835"}, {"groupId": "OG003", "value": "-0.17", "spread": "0.603"}]}]}, {"title": "PAPi: 2 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.38", "spread": "0.435"}, {"groupId": "OG001", "value": "0.33", "spread": "0.058"}, {"groupId": "OG002", "value": "-0.14", "spread": "1.011"}, {"groupId": "OG003", "value": "0.20", "spread": "0.900"}]}]}, {"title": "PAPi: 3 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.65", "spread": "0.624"}, {"groupId": "OG001", "value": "0.43", "spread": "0.777"}, {"groupId": "OG002", "value": "0.03", "spread": "0.897"}, {"groupId": "OG003", "value": "-0.33", "spread": "0.611"}]}]}, {"title": "PAPi: 4 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.35", "spread": "1.838"}, {"groupId": "OG001", "value": "0.83", "spread": "1.834"}, {"groupId": "OG002", "value": "0.27", "spread": "1.203"}, {"groupId": "OG003", "value": "-1.03", "spread": "0.907"}]}]}, {"title": "PAPi: 5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.95", "spread": "0.597"}, {"groupId": "OG001", "value": "2.33", "spread": "1.818"}, {"groupId": "OG002", "value": "-0.01", "spread": "0.872"}, {"groupId": "OG003", "value": "0.87", "spread": "2.639"}]}]}, {"title": "PAPi: 6 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.93", "spread": "0.929"}, {"groupId": "OG001", "value": "1.27", "spread": "0.929"}, {"groupId": "OG002", "value": "0.77", "spread": "2.470"}, {"groupId": "OG003", "value": "-0.90", "spread": "0.173"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Systemic Vascular Resistance Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "Systemic vascular resistance (SVR) is the amount of force exerted on circulating blood by the vasculature of the body. SVR was calculated as 80\\*(mean arterial pressure - mean venous pressure) divided by cardiac output. Change in SVR measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6-hour IV infusion was reported in this outcome measure.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment. All participants reported under 'Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row. Here, 'Number Analyzed' (n) signifies number of participants evaluable for specified timepoints.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Millimeter of mercury*minutes/milliliter", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "SVR: 0.5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.30", "spread": "74.776"}, {"groupId": "OG001", "value": "-71.27", "spread": "55.492"}, {"groupId": "OG002", "value": "-47.30", "spread": "139.874"}, {"groupId": "OG003", "value": "74.13", "spread": "198.427"}]}]}, {"title": "SVR: 1 hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-80.50", "spread": "57.295"}, {"groupId": "OG001", "value": "-86.30", "spread": "80.694"}, {"groupId": "OG002", "value": "16.71", "spread": "231.657"}, {"groupId": "OG003", "value": "-131.93", "spread": "91.886"}]}]}, {"title": "SVR: 2 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-48.83", "spread": "71.811"}, {"groupId": "OG001", "value": "-46.23", "spread": "28.762"}, {"groupId": "OG002", "value": "-42.16", "spread": "205.772"}, {"groupId": "OG003", "value": "-49.40", "spread": "136.124"}]}]}, {"title": "SVR: 3 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-67.63", "spread": "56.169"}, {"groupId": "OG001", "value": "-8.10", "spread": "102.327"}, {"groupId": "OG002", "value": "-101.20", "spread": "188.863"}, {"groupId": "OG003", "value": "-195.77", "spread": "101.041"}]}]}, {"title": "SVR: 4 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-27.20", "spread": "104.351"}, {"groupId": "OG001", "value": "73.90", "spread": "136.245"}, {"groupId": "OG002", "value": "-33.91", "spread": "241.040"}, {"groupId": "OG003", "value": "-311.03", "spread": "145.094"}]}]}, {"title": "SVR: 5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "21.10", "spread": "112.824"}, {"groupId": "OG001", "value": "132.63", "spread": "171.630"}, {"groupId": "OG002", "value": "-92.29", "spread": "94.834"}, {"groupId": "OG003", "value": "-110.57", "spread": "222.498"}]}]}, {"title": "SVR: 6 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "33.10", "spread": "106.652"}, {"groupId": "OG001", "value": "90.37", "spread": "137.576"}, {"groupId": "OG002", "value": "-70.00", "spread": "116.681"}, {"groupId": "OG003", "value": "-104.23", "spread": "90.537"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Systemic Vascular Resistance Index (SVRI) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "SVRI was calculated by dividing the difference between mean arterial pressure and central venous pressure by cardiac index and multiplying by 80. Change in SVRI measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6 hour IV infusion was reported in this outcome measure.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment. All participants reported under 'Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row. Here, 'Number Analyzed' (n) signifies number of participants evaluable for specified timepoints.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Dynes*second*meter^2 per centimeter^5", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "SVRI: 0.5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.00", "spread": "157.514"}, {"groupId": "OG001", "value": "-171.20", "spread": "154.962"}, {"groupId": "OG002", "value": "-98.41", "spread": "270.327"}, {"groupId": "OG003", "value": "107.83", "spread": "428.022"}]}]}, {"title": "SVRI: 1 hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-156.58", "spread": "105.011"}, {"groupId": "OG001", "value": "-202.73", "spread": "185.527"}, {"groupId": "OG002", "value": "16.20", "spread": "404.144"}, {"groupId": "OG003", "value": "-289.57", "spread": "102.838"}]}]}, {"title": "SVRI: 2 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-115.13", "spread": "165.795"}, {"groupId": "OG001", "value": "-85.30", "spread": "63.286"}, {"groupId": "OG002", "value": "-94.82", "spread": "407.893"}, {"groupId": "OG003", "value": "-64.77", "spread": "281.682"}]}]}, {"title": "SVRI: 3 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-152.98", "spread": "108.934"}, {"groupId": "OG001", "value": "-42.57", "spread": "192.932"}, {"groupId": "OG002", "value": "-190.53", "spread": "315.500"}, {"groupId": "OG003", "value": "-403.47", "spread": "271.919"}]}]}, {"title": "SVRI: 4 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-85.05", "spread": "224.198"}, {"groupId": "OG001", "value": "201.20", "spread": "357.587"}, {"groupId": "OG002", "value": "-31.66", "spread": "414.786"}, {"groupId": "OG003", "value": "-649.80", "spread": "360.988"}]}]}, {"title": "SVRI: 5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12.80", "spread": "208.554"}, {"groupId": "OG001", "value": "350.47", "spread": "458.646"}, {"groupId": "OG002", "value": "-172.77", "spread": "186.678"}, {"groupId": "OG003", "value": "-260.83", "spread": "484.601"}]}]}, {"title": "SVRI: 6 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "61.47", "spread": "205.227"}, {"groupId": "OG001", "value": "152.63", "spread": "171.695"}, {"groupId": "OG002", "value": "-94.08", "spread": "306.599"}, {"groupId": "OG003", "value": "-227.17", "spread": "126.337"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Pulmonary Vascular Resistance (PVR) Measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "PVR is the resistance against blood flow from the pulmonary artery to the left atrium. Change in PVR measured by RHC at 0.5, 1, 2, 3, 4, 5 and 6 hours during the 6 hour IV infusion was reported in this outcome measure.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment. All participants reported under 'Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row. Here, 'Number Analyzed' (n) signifies number of participants evaluable for specified timepoints.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "dynes*second per centimeter^5", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "PVR: 0.5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.98", "spread": "21.955"}, {"groupId": "OG001", "value": "-97.13", "spread": "134.474"}, {"groupId": "OG002", "value": "14.83", "spread": "115.974"}, {"groupId": "OG003", "value": "83.40", "spread": "80.442"}]}]}, {"title": "PVR: 1 hour", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.80", "spread": "108.571"}, {"groupId": "OG001", "value": "-37.57", "spread": "102.284"}, {"groupId": "OG002", "value": "78.37", "spread": "235.884"}, {"groupId": "OG003", "value": "6.40", "spread": "115.783"}]}]}, {"title": "PVR: 2 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "37.68", "spread": "106.364"}, {"groupId": "OG001", "value": "46.43", "spread": "27.918"}, {"groupId": "OG002", "value": "-1.64", "spread": "290.121"}, {"groupId": "OG003", "value": "-0.10", "spread": "136.989"}]}]}, {"title": "PVR: 3 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "29.70", "spread": "99.607"}, {"groupId": "OG001", "value": "-11.60", "spread": "69.295"}, {"groupId": "OG002", "value": "36.04", "spread": "171.091"}, {"groupId": "OG003", "value": "18.13", "spread": "107.316"}]}]}, {"title": "PVR: 4 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "32.28", "spread": "190.279"}, {"groupId": "OG001", "value": "10.03", "spread": "72.673"}, {"groupId": "OG002", "value": "32.44", "spread": "191.341"}, {"groupId": "OG003", "value": "-44.03", "spread": "121.310"}]}]}, {"title": "PVR: 5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "29.08", "spread": "163.825"}, {"groupId": "OG001", "value": "44.57", "spread": "38.099"}, {"groupId": "OG002", "value": "22.61", "spread": "195.626"}, {"groupId": "OG003", "value": "53.70", "spread": "211.590"}]}]}, {"title": "PVR: 6 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "8"}, {"groupId": "OG003", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.70", "spread": "150.529"}, {"groupId": "OG001", "value": "54.57", "spread": "15.245"}, {"groupId": "OG002", "value": "38.10", "spread": "291.188"}, {"groupId": "OG003", "value": "19.53", "spread": "86.649"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "SBP, DBP and MAP were measured in a supine or seated position after participant had at least 5 minutes of rest. MAP is the average pressure of the blood circulating through a participant's arteries during the cardiac cycle. MAP was derived by using the following formula: DBP + 1/3(SBP-DBP).", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Millimeters of mercury", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "SBP: 0.5 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.3", "spread": "10.21"}, {"groupId": "OG001", "value": "-11.0", "spread": "10.15"}, {"groupId": "OG002", "value": "-2.2", "spread": "11.47"}, {"groupId": "OG003", "value": "-0.5", "spread": "6.35"}]}]}, {"title": "SBP: 1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.8", "spread": "10.56"}, {"groupId": "OG001", "value": "-7.3", "spread": "1.53"}, {"groupId": "OG002", "value": "-3.8", "spread": "9.44"}, {"groupId": "OG003", "value": "-0.8", "spread": "6.18"}]}]}, {"title": "SBP: 2 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.0", "spread": "14.54"}, {"groupId": "OG001", "value": "-6.3", "spread": "9.81"}, {"groupId": "OG002", "value": "-2.6", "spread": "11.21"}, {"groupId": "OG003", "value": "0.5", "spread": "6.14"}]}]}, {"title": "SBP: 3 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "14.07"}, {"groupId": "OG001", "value": "-4.7", "spread": "7.77"}, {"groupId": "OG002", "value": "-3.9", "spread": "10.35"}, {"groupId": "OG003", "value": "-1.0", "spread": "10.30"}]}]}, {"title": "SBP: 4 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.5", "spread": "15.11"}, {"groupId": "OG001", "value": "-2.7", "spread": "8.33"}, {"groupId": "OG002", "value": "-3.9", "spread": "9.66"}, {"groupId": "OG003", "value": "0.5", "spread": "14.93"}]}]}, {"title": "SBP: 6 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.8", "spread": "12.45"}, {"groupId": "OG001", "value": "-5.0", "spread": "6.00"}, {"groupId": "OG002", "value": "-1.4", "spread": "8.90"}, {"groupId": "OG003", "value": "-1.0", "spread": "12.57"}]}]}, {"title": "DBP: 0.5 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "16.06"}, {"groupId": "OG001", "value": "-6.7", "spread": "7.02"}, {"groupId": "OG002", "value": "-0.2", "spread": "4.92"}, {"groupId": "OG003", "value": "0.0", "spread": "4.24"}]}]}, {"title": "DBP: 1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "14.85"}, {"groupId": "OG001", "value": "-4.0", "spread": "5.29"}, {"groupId": "OG002", "value": "-2.2", "spread": "5.74"}, {"groupId": "OG003", "value": "7.0", "spread": "18.20"}]}]}, {"title": "DBP: 2 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.0", "spread": "16.12"}, {"groupId": "OG001", "value": "-7.0", "spread": "2.65"}, {"groupId": "OG002", "value": "0.0", "spread": "7.92"}, {"groupId": "OG003", "value": "-1.5", "spread": "5.92"}]}]}, {"title": "DBP: 3 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.0", "spread": "12.46"}, {"groupId": "OG001", "value": "-3.3", "spread": "5.13"}, {"groupId": "OG002", "value": "-4.8", "spread": "9.26"}, {"groupId": "OG003", "value": "-1.0", "spread": "7.79"}]}]}, {"title": "DBP: 4 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.8", "spread": "13.10"}, {"groupId": "OG001", "value": "0.3", "spread": "7.77"}, {"groupId": "OG002", "value": "-6.3", "spread": "5.76"}, {"groupId": "OG003", "value": "-1.0", "spread": "5.72"}]}]}, {"title": "DBP: 5 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "13.67"}, {"groupId": "OG001", "value": "-2.0", "spread": "1.73"}, {"groupId": "OG002", "value": "-6.8", "spread": "6.52"}, {"groupId": "OG003", "value": "-1.0", "spread": "6.98"}]}]}, {"title": "DBP: 6 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "13.57"}, {"groupId": "OG001", "value": "1.3", "spread": "2.08"}, {"groupId": "OG002", "value": "-0.3", "spread": "6.87"}, {"groupId": "OG003", "value": "3.8", "spread": "7.93"}]}]}, {"title": "MAP: 0.5 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.42", "spread": "13.723"}, {"groupId": "OG001", "value": "-8.11", "spread": "8.002"}, {"groupId": "OG002", "value": "-0.85", "spread": "4.994"}, {"groupId": "OG003", "value": "-0.17", "spread": "4.041"}]}]}, {"title": "MAP: 1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.25", "spread": "12.971"}, {"groupId": "OG001", "value": "-5.11", "spread": "3.097"}, {"groupId": "OG002", "value": "-2.73", "spread": "4.718"}, {"groupId": "OG003", "value": "4.42", "spread": "10.651"}]}]}, {"title": "MAP: 2 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.33", "spread": "13.891"}, {"groupId": "OG001", "value": "-6.78", "spread": "4.623"}, {"groupId": "OG002", "value": "-0.88", "spread": "6.634"}, {"groupId": "OG003", "value": "-0.83", "spread": "5.828"}]}]}, {"title": "MAP: 3 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.00", "spread": "12.640"}, {"groupId": "OG001", "value": "-3.78", "spread": "5.274"}, {"groupId": "OG002", "value": "-4.52", "spread": "7.752"}, {"groupId": "OG003", "value": "-1.00", "spread": "8.551"}]}]}, {"title": "MAP: 4 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.00", "spread": "13.101"}, {"groupId": "OG001", "value": "-0.67", "spread": "6.960"}, {"groupId": "OG002", "value": "-5.48", "spread": "5.768"}, {"groupId": "OG003", "value": "-0.50", "spread": "8.131"}]}]}, {"title": "MAP: 5 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.33", "spread": "13.570"}, {"groupId": "OG001", "value": "-1.00", "spread": "5.196"}, {"groupId": "OG002", "value": "-7.30", "spread": "5.742"}, {"groupId": "OG003", "value": "-0.17", "spread": "7.466"}]}]}, {"title": "MAP: 6 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.08", "spread": "12.900"}, {"groupId": "OG001", "value": "-0.78", "spread": "1.388"}, {"groupId": "OG002", "value": "-0.64", "spread": "5.934"}, {"groupId": "OG003", "value": "2.17", "spread": "9.406"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Change in Heart Rate at 0.5, 1, 2, 3, 4, 5 and 6 Hours", "description": "Heart rate was measured in a supine or seated position after participant had at least 5 minutes of rest.", "populationDescription": "Full analysis set included all randomized participants, irrespective of whether they received any study treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Beats per minute", "timeFrame": "Baseline (within 2 hours prior to start of study treatment administration), 0.5, 1, 2, 3, 4, 5 and 6 hours of IV infusion", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"title": "0.5 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.8", "spread": "9.00"}, {"groupId": "OG001", "value": "-7.3", "spread": "12.66"}, {"groupId": "OG002", "value": "0.0", "spread": "5.93"}, {"groupId": "OG003", "value": "3.5", "spread": "9.11"}]}]}, {"title": "1 hour", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.5", "spread": "2.65"}, {"groupId": "OG001", "value": "-3.3", "spread": "14.19"}, {"groupId": "OG002", "value": "-1.6", "spread": "4.86"}, {"groupId": "OG003", "value": "-9.0", "spread": "13.29"}]}]}, {"title": "2 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "5.32"}, {"groupId": "OG001", "value": "-0.7", "spread": "9.07"}, {"groupId": "OG002", "value": "-1.5", "spread": "6.62"}, {"groupId": "OG003", "value": "-7.0", "spread": "13.49"}]}]}, {"title": "3 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "8.87"}, {"groupId": "OG001", "value": "0.0", "spread": "9.17"}, {"groupId": "OG002", "value": "-0.6", "spread": "8.31"}, {"groupId": "OG003", "value": "-5.3", "spread": "11.18"}]}]}, {"title": "4 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "6.24"}, {"groupId": "OG001", "value": "0.3", "spread": "14.22"}, {"groupId": "OG002", "value": "-1.1", "spread": "5.80"}, {"groupId": "OG003", "value": "1.0", "spread": "20.02"}]}]}, {"title": "5 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.3", "spread": "6.08"}, {"groupId": "OG001", "value": "-1.7", "spread": "5.86"}, {"groupId": "OG002", "value": "-1.5", "spread": "5.77"}, {"groupId": "OG003", "value": "-5.0", "spread": "13.49"}]}]}, {"title": "6 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.5", "spread": "9.00"}, {"groupId": "OG001", "value": "1.0", "spread": "5.57"}, {"groupId": "OG002", "value": "4.2", "spread": "9.22"}, {"groupId": "OG003", "value": "-1.5", "spread": "17.82"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)", "description": "An AE was any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. TEAEs were defined as those AEs with onset after start date/timepoint of study drug administration.", "populationDescription": "Safety set included all randomized participants who received at least one dose of study treatment.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From start of study treatment on Day 1 up to Day 9", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Area Under the Plasma Concentration Time Curve From Time Zero to 6 Hours (AUC[0-6]) of APD418", "description": "AUC \\[0-6\\] was reported in this outcome measure.", "populationDescription": "Pharmacokinetic (PK) set included all participants in the safety set with at least 1 post-dose PK measurement.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Hours*nanogram per milliliter", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6620", "spread": "68.7"}, {"groupId": "OG001", "value": "5970", "spread": "268"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Area Under the Plasma Concentration Time Curve From Time Zero to Last Quantifiable Plasma Concentration (AUCLast) of APD418", "description": "AUClast was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Hours*nanogram per milliliter", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9410", "spread": "84.3"}, {"groupId": "OG001", "value": "9230", "spread": "164"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Area Under the Plasma Concentration Time Curve From Time Zero up to Infinity (AUC[0-Infinity]) of APD418", "description": "AUC \\[0-infinity\\] was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement. Here, \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Hours*nanogram per milliliter", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9660", "spread": "87.0"}, {"groupId": "OG001", "value": "13400", "spread": "34.5"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Maximum Observed Plasma Concentration (Cmax) of APD418", "description": "Cmax of APD418 was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanogram per milliliter", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1540", "spread": "88.8"}, {"groupId": "OG001", "value": "1480", "spread": "277"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Terminal Elimination Half-Life (t1/2) for APD418", "description": "Terminal t1/2 of APD418 was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement. Here, \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Hours", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.26", "spread": "0.960"}, {"groupId": "OG001", "value": "5.26", "spread": "0.998"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Distributional Half-Life (t1/2a) for APD418", "description": "Distributional t1/2 of APD418 was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement. Here, \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Hours", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.579", "spread": "0.381"}, {"groupId": "OG001", "value": "0.381", "spread": "0.119"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Time to Maximum Observed Plasma Concentration (Tmax) for APD418", "description": "Tmax of APD418 was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Hours", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.42", "lowerLimit": "4.00", "upperLimit": "6.08"}, {"groupId": "OG001", "value": "5.00", "lowerLimit": "0.500", "upperLimit": "6.18"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Total Clearance (CL) for APD418", "description": "IV CL of APD418 was reported in this outcome measure.", "populationDescription": "The PK set included all participants in the safety set with at least 1 post-dose PK measurement. Here, \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Liter per hour", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.16", "spread": "92.7"}, {"groupId": "OG001", "value": "17.8", "spread": "23.2"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Total Volume of Distribution Based on the Terminal Phase (Vdz) for APD418", "description": "Vdz of APD418 was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement. Here, \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Liter", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "68.6", "spread": "74.5"}, {"groupId": "OG001", "value": "133", "spread": "28.6"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Volume of Distribution at Steady State (Vdss) for APD418", "description": "Vdss of APD418 was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement. Here, \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Liter", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27.7", "spread": "42.2"}, {"groupId": "OG001", "value": "46.0", "spread": "34.5"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Mean Residence Time From Time Zero to Time of Last Quantifiable Plasma Concentration (MRTlast) for APD418", "description": "MRTlast of APD418 was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Hours", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 6.083, 6.167, 6.25, 6.5, 7, 8, 10, 18 and 24 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.44", "spread": "33.6"}, {"groupId": "OG001", "value": "2.54", "spread": "74.3"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Average Plasma Concentration During Dosing Interval (Cave) for ADP418", "description": "Average plasma concentration calculated over the 6-hour infusion time was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Nanogram per milliliter", "timeFrame": "Pre-dose, 0.5, 1, 2, 3, 4, 5, 6 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1100", "spread": "68.7"}, {"groupId": "OG001", "value": "996", "spread": "268"}]}]}]}, {"type": "SECONDARY", "title": "Part A: Renal Clearance (CLr) for ADP418", "description": "CLr for APD418 was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Liter per hour", "timeFrame": "Pre-dose (0) to 24 hours post infusion start, collected over 0 to 6 hour, 6 to 10 hour and 10 to 24-hour intervals", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.14", "spread": "55.3"}, {"groupId": "OG001", "value": "3.78", "spread": "54.8"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Part A: Amount of Unchanged Drug Excreted in Urine During Each Collection Interval From t1 to t2 (Aet1-t2)", "description": "Amount of unchanged drug excreted in urine during each collection interval from t1 to t2 was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Milligrams", "timeFrame": "Anytime between 0 to 6 hours, 6 to 10 hours and 10 to 24 hours post infusion start", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"title": "Ae 0-6", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.8", "spread": "26.7"}, {"groupId": "OG001", "value": "25.6", "spread": "56.9"}]}]}, {"title": "Ae 6-10", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.47", "spread": "27.3"}, {"groupId": "OG001", "value": "7.68", "spread": "68.4"}]}]}, {"title": "Ae 10-24", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.83", "spread": "136"}, {"groupId": "OG001", "value": "7.93", "spread": "172"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Part A: Total Amount of Unchanged Drug Excreted in Urine Over the Collection Period (Amount Excreted [Ae])", "description": "Total amount of unchanged drug excreted in urine over the collection period was reported in this outcome measure.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Milligrams", "timeFrame": "Pre-dose (0) to 24 hours post infusion start, collected over 0 to 6 hour, 6 to 10 hour and 10 to 24-hour intervals", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.1", "spread": "28.8"}, {"groupId": "OG001", "value": "48.5", "spread": "38.0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Part A: Fraction of Drug Excreted Unchanged (Fe) in Urine", "description": "Fraction of drug excreted in urine was reported in this outcome measure. Data is presented in terms of percentages.", "populationDescription": "PK set included all participants in the safety set with at least 1 post-dose PK measurement.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Percentage of unchanged drug", "timeFrame": "Pre-dose (0) to 24 hours post infusion start, collected over 0 to 6 hour, 6 to 10 hour and 10 to 24-hour intervals", "groups": [{"id": "OG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}, {"id": "OG001", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.7", "spread": "31.2"}, {"groupId": "OG001", "value": "19.7", "spread": "39.8"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "From start of study treatment on Day 1 up to Day 9", "description": "Safety set included all randomized participants who received at least one dose of study treatment.", "eventGroups": [{"id": "EG000", "title": "Cohort 1- 0.17 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.17 milligrams per kilogram per hour (mg/kg/hr) (total dose of 1 mg/kg) APD418 as an intravenous (IV) infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period.", "deathsNumAffected": 0, "deathsNumAtRisk": 4, "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 1, "otherNumAtRisk": 4}, {"id": "EG001", "title": "Cohort 1- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period.", "deathsNumAffected": 0, "deathsNumAtRisk": 3, "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 1, "otherNumAtRisk": 3}, {"id": "EG002", "title": "Cohort 2- 0.5 mg/kg/hr APD418", "description": "Participants were administered a single dose of 0.5 mg/kg/hr (total dose of 3 mg/kg) APD418 as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period.", "deathsNumAffected": 0, "deathsNumAtRisk": 11, "seriousNumAffected": 0, "seriousNumAtRisk": 11, "otherNumAffected": 3, "otherNumAtRisk": 11}, {"id": "EG003", "title": "Cohort 2- Placebo", "description": "Participants were administered a single dose of matching placebo as an IV infusion over a duration of 6 hours on Day 1 (Dosing Period) followed by an 18 to 24-hour in-clinic observation period.", "deathsNumAffected": 0, "deathsNumAtRisk": 4, "seriousNumAffected": 0, "seriousNumAtRisk": 4, "otherNumAffected": 1, "otherNumAtRisk": 4}], "otherEvents": [{"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA v24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 4}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 4}]}, {"term": "N-terminal prohormone brain natriuretic peptide increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA v24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 4}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 4}]}, {"term": "Vein rupture", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v24.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 4}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 4}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "This study was terminated early due to a business decision that was not due to any safety concerns. The number of participants was smaller than originally planned and only summary statistics were therefore generated for primary and secondary outcome measures."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."}, "pointOfContact": {"title": "Pfizer ClinicalTrials.gov Call Center", "organization": "Pfizer Inc.", "email": "ClinicalTrials.gov_Inquiries@pfizer.com", "phone": "1-800-718-1021"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2022-04-26", "uploadDate": "2023-09-18T10:36", "filename": "Prot_SAP_000.pdf", "size": 5224422}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Former Serbia and Montenegro"], "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-10-13", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": true}